Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MC, Caramella M, Rumi E, Carraro MC, Polverelli N, D'Adda M, Malato S, Rossi M, Molteni A, Vismara A, Sissa C, Spina F, Anghilieri M, Cattaneo D, Renso R, Bellini M, Pioltelli ML, Cavalloni C, Barraco D, Accetta R, Bertù L, Della Porta MG, Passamonti F.

Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646. No abstract available.

2.

Standard care and investigational drugs in the treatment of myelofibrosis.

Barraco D, Maffioli M, Passamonti F.

Drugs Context. 2019 Sep 26;8:212603. doi: 10.7573/dic.212603. eCollection 2019. Review.

3.

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.

Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25644. [Epub ahead of print] No abstract available.

PMID:
31588594
4.

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F.

Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.

5.

Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).

Elli EM, Iurlo A, Aroldi A, Caramella M, Malato S, Casartelli E, Maffioli M, Gardellini A, Carraro MC, D'Adda M, Polverelli N, Rossi M, Orofino N, Carrer A, Gambacorti-Passerini C, Antolini L, Passamonti F.

Br J Haematol. 2019 Sep;186(5):e123-e126. doi: 10.1111/bjh.15964. Epub 2019 May 20. No abstract available.

PMID:
31106402
6.

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Durrant ST, Nagler A, Guglielmelli P, Lavie D, le Coutre P, Gisslinger H, Chuah C, Maffioli M, Bharathy S, Dong T, Wroclawska M, Lopez JM.

Haematologica. 2019 Dec;104(12):e551-e554. doi: 10.3324/haematol.2018.209965. Epub 2019 May 9. No abstract available.

7.

Treating early-stage myelofibrosis.

Palandri F, Sabattini E, Maffioli M.

Ann Hematol. 2019 Feb;98(2):241-253. doi: 10.1007/s00277-018-3526-z. Epub 2018 Oct 20. Review.

PMID:
30343328
8.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

9.

Chronic myeloproliferative neoplasms in the elderly.

Maffioli M, Orlandi E, Passamonti F.

Eur J Intern Med. 2018 Dec;58:33-42. doi: 10.1016/j.ejim.2018.05.005. Epub 2018 May 22. Review.

PMID:
29793825
10.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
11.

Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Passamonti F, Mora B, Barraco D, Maffioli M.

Curr Hematol Malig Rep. 2018 Jun;13(3):173-182. doi: 10.1007/s11899-018-0453-y. Review.

PMID:
29713873
12.

The role of JAK2 inhibitors in MPNs 7 years after approval.

Passamonti F, Maffioli M.

Blood. 2018 May 31;131(22):2426-2435. doi: 10.1182/blood-2018-01-791491. Epub 2018 Apr 12.

PMID:
29650801
13.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. No abstract available.

14.

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.

Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L.

Qual Life Res. 2018 Jun;27(6):1545-1554. doi: 10.1007/s11136-018-1827-2. Epub 2018 Mar 8.

PMID:
29520559
15.

Retropharyngeal Space Schwannoma: A Rare Entity.

Gallo S, Bandi F, Maffioli MP, Giudice M, Castelnuovo P, Fazio E, Karligkiotis A.

Iran J Otorhinolaryngol. 2017 Nov;29(95):353-357.

16.

Therapy of polycythemia vera: is it time to change?

Passamonti F, Maffioli M, Mora B.

Oncotarget. 2017 Nov 3;8(61):102759-102760. doi: 10.18632/oncotarget.22282. eCollection 2017 Nov 28. No abstract available.

17.

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.

Maffioli M, Mora B, Passamonti F.

Clin Adv Hematol Oncol. 2017 Sep;15(9):700-707. Review.

PMID:
28949941
18.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM.

Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.

PMID:
28561069
19.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pietra D, Salmoiraghi S, Mannarelli C, Franci A, Paoli C, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM; AGIMM Group.

Blood. 2017 Jun 15;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999. Epub 2017 Mar 28.

PMID:
28351937
20.

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

Ferrario A, Merli M, Basilico C, Maffioli M, Passamonti F.

Expert Opin Investig Drugs. 2017 Mar;26(3):367-373. doi: 10.1080/13543784.2017.1288213. Epub 2017 Feb 9. Review.

PMID:
28140696
21.

Update from the latest WHO classification of MPNs: a user's manual.

Passamonti F, Maffioli M.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):534-542. Review.

22.

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM.

Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25. No abstract available.

PMID:
27885272
23.

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.

Merli M, Ferrario A, Maffioli M, Olivares C, Stasia A, Arcaini L, Passamonti F.

Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14. Review.

PMID:
27416486
24.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pieri L, Fjerza R, Pietra D, Cilloni D, Sant'Antonio E, Salmoiraghi S, Passamonti F, Rambaldi A, Barosi G, Barbui T, Cazzola M, Vannucchi AM.

Am J Hematol. 2016 Sep;91(9):918-22. doi: 10.1002/ajh.24442. Epub 2016 Jul 4.

25.

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis.

Breccia M, Graffigna G, Galimberti S, Iurlo A, Pungolino E, Pizzuti M, Maggi A, Falzetti F, Capalbo SF, Intermesoli T, Maffioli M, Elena C, Melosi A, Simonetti F, Capochiani E, Seta RD, Pacilli M, Luppi M, Di Renzo N, Mastrullo L, Trabacchi E, Vallisa D, Rapezzi D, Orlandi EM, Gambacorti-Passerini C, Efficace F, Alimena G.

Support Care Cancer. 2016 Nov;24(11):4487-93. doi: 10.1007/s00520-016-3286-z. Epub 2016 Jun 3.

PMID:
27260015
26.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P.

Am J Hematol. 2016 Jul;91(7):681-6. doi: 10.1002/ajh.24377. Epub 2016 May 11.

27.

New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms.

Passamonti F, Mora B, Maffioli M.

Curr Opin Hematol. 2016 Mar;23(2):137-43. doi: 10.1097/MOH.0000000000000218. Review.

PMID:
26825696
28.

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.

Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F.

Expert Opin Investig Drugs. 2015;24(7):897-912. doi: 10.1517/13543784.2015.1038342. Epub 2015 Apr 21. Review.

PMID:
25900401
29.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

Kröger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg HJ, Passamonti F.

Blood. 2015 May 21;125(21):3347-50; quiz 3364. doi: 10.1182/blood-2014-10-608315. Epub 2015 Mar 17.

30.

Everolimus in diffuse large B-cell lymphomas.

Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F.

Future Oncol. 2015;11(3):373-83. doi: 10.2217/fon.14.264. Review.

PMID:
25675120
31.

Acquired tracheal dilatation after prolonged ventilation: an unusual treatment option.

Giudice M, Gallo S, Maffioli MP, Minoja G, Mazzi G, Narne S, Castelnuovo P.

Laryngoscope. 2014 Oct;124(10):2309-12. doi: 10.1002/lary.24645. Epub 2014 Apr 2. No abstract available.

PMID:
25265275
32.

It is time to change thrombosis risk assessment for PV and ET?

Passamonti F, Caramazza D, Mora B, Casalone R, Maffioli M.

Best Pract Res Clin Haematol. 2014 Jun;27(2):121-7. doi: 10.1016/j.beha.2014.07.005. Epub 2014 Jul 18. Review.

PMID:
25189723
33.

Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.

Gangat N, Wassie EA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Passamonti F, Tefferi A.

Eur J Haematol. 2015 Jan;94(1):31-6. doi: 10.1111/ejh.12389. Epub 2014 Dec 4.

PMID:
24889737
34.

Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.

Dentali F, Ageno W, Rumi E, Casetti I, Poli D, Scoditti U, Maffioli M, di Minno MN, Caramazza D, Pietra D, De Stefano V, Passamonti F.

Thromb Res. 2014 Jul;134(1):41-3. doi: 10.1016/j.thromres.2014.03.040. Epub 2014 Mar 29.

PMID:
24787989
35.

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.

Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F.

Am J Hematol. 2014 Aug;89(8):E121-4. doi: 10.1002/ajh.23743. Epub 2014 May 16.

36.

JAK inhibitor in CALR-mutant myelofibrosis.

Passamonti F, Caramazza D, Maffioli M.

N Engl J Med. 2014 Mar 20;370(12):1168-9. doi: 10.1056/NEJMc1400499. No abstract available.

PMID:
24645956
37.

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M.

Blood. 2014 Mar 20;123(12):1833-5. doi: 10.1182/blood-2013-12-544411. Epub 2014 Jan 17.

PMID:
24443442
38.

Looking for CALR mutations in familial myeloproliferative neoplasms.

Maffioli M, Genoni A, Caramazza D, Mora B, Bussini A, Merli M, Giorgino T, Casalone R, Passamonti F.

Leukemia. 2014 Jun;28(6):1357-60. doi: 10.1038/leu.2014.33. Epub 2014 Jan 20. No abstract available.

PMID:
24441291
39.

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A.

Leukemia. 2014 Jul;28(7):1472-7. doi: 10.1038/leu.2014.3. Epub 2014 Jan 9.

PMID:
24402162
40.

Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.

Martínez-Trillos A, Maffioli M, Colomer D, Alvarez-Larrán A, Pereira A, Angona A, Bellosillo B, Cervantes F.

Ann Hematol. 2014 May;93(5):797-802. doi: 10.1007/s00277-013-1989-5. Epub 2013 Dec 15.

PMID:
24337516
41.

Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma.

Merli M, Maffioli M, Ferrario A, Passamonti F.

Am J Hematol. 2013 Aug;88(8):719-20. doi: 10.1002/ajh.23482. Epub 2013 Jul 3. No abstract available.

42.

Novel agents in indolent lymphomas.

Merli M, Ferrario A, Basilico C, Maffioli M, Caramazza D, Appio L, Arcaini L, Passamonti F.

Ther Adv Hematol. 2013 Apr;4(2):133-48. doi: 10.1177/2040620712466865.

43.

Clinical predictors of outcome in MPN.

Passamonti F, Maffioli M, Merli M, Ferrario A, Caramazza D.

Hematol Oncol Clin North Am. 2012 Oct;26(5):1101-16. doi: 10.1016/j.hoc.2012.07.009. Epub 2012 Aug 28. Review.

PMID:
23009940
44.

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A.

Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26.

PMID:
22740446
45.

A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.

Hernández-Boluda JC, Pereira A, Cervantes F, Alvarez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy B, Maffioli M, Bellosillo B, Marugán I, Amat P, Besses C, Guillem V.

Blood. 2012 May 31;119(22):5221-8. doi: 10.1182/blood-2012-02-411215. Epub 2012 Apr 11.

PMID:
22496165
46.

New generation small-molecule inhibitors in myeloproliferative neoplasms.

Passamonti F, Maffioli M, Caramazza D.

Curr Opin Hematol. 2012 Mar;19(2):117-23. doi: 10.1097/MOH.0b013e32834ff575. Review.

PMID:
22227528
47.

EZH2 mutational status predicts poor survival in myelofibrosis.

Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM.

Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14.

PMID:
21921040
48.

Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.

Nomdedeu M, Maffioli M, Calvo X, Martínez-Trillos A, Baumann T, Díaz-Beyá M, Aguilar JL, Rozman M, Costa D, Esteve J, Cervantes F, Colomer D, Nomdedeu B.

Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20. No abstract available.

PMID:
21764129
49.

Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.

Guillem V, Amat P, Cervantes F, Alvarez-Larrán A, Cervera J, Maffioli M, Bellosillo B, Collado M, Marugán I, Martínez-Ruiz F, Hernández-Boluda JC.

Leuk Res. 2012 Feb;36(2):174-81. doi: 10.1016/j.leukres.2011.06.011. Epub 2011 Jul 2.

PMID:
21724255
50.

Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.

Passamonti F, Maffioli M, Caramazza D, Cazzola M.

Oncotarget. 2011 Jun;2(6):485-90.

Supplemental Content

Loading ...
Support Center